JCSE 01.12 – A phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116) (WCLC 2017)

Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su

 HMPL-013_Ph2_NSCLC_Iressa_Combo_WCLC_2017_thumb

Venue: IASLC 18th World Conference on Lung Cancer in in Yokohama, Japan
Session: JCSE 01 – Joint IASLC / CSCO / CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West (ID 630)
Presenter: J Zhou
Date: Sunday, October 15, 2017

For a summary of the data presented, please see the Chi-Med company overview presentation.